Hospital
Duncan Regional Hospital, INC.
Duncan Regional Hospital, INC. was paid $17.79M by Medicaid between Jan 2018 and Nov 2024, across 112 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoDUNCAN REGIONAL HOSPITAL, INC.
DUNCAN, OK 73533
DUNCAN, OK 73533
33aNPI1851396394assigned 06/20/2005
33bProvider typeRural Acute Care Hospital
28Total paid$17.79M
24GClaims259,713
24DCodes billed112
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Oklahoma
Rank by total paid#1 of 10
Median peer was paid$1.46M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,827 | $1.67M | |
| 2019 | 26,907 | $1.72M | |
| 2020 | 24,424 | $1.62M | |
| 2021 | 38,514 | $2.78M | |
| 2022 | 55,285 | $4.03M | |
| 2023 | 63,250 | $4.09M | |
| 2024incomplete | 25,506 | $1.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 22,007 | 21,561 | $5.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 12,310 | 12,082 | $3.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 20,084 | 19,838 | $3.28M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.7% | 11,809 | 11,543 | $1.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 2,910 | 2,886 | $474K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.8% | 2,423 | 2,410 | $326K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 7,627 | 7,448 | $314K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 4,115 | 1,284 | $246K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 3,416 | 3,346 | $236K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 3,320 | 1,157 | $222K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 561 | 560 | $181K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,483 | 1,053 | $164K |
100 more codes
| 80053 | Comprehensive metabolic panel | <1% | 16,860 | $149K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,999 | $145K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 38 | $142K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,407 | $139K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,133 | $105K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,875 | $96K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,281 | $94K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,324 | $90K |
| 80081 | <1% | 1,259 | $78K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 12,239 | $77K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 140 | $67K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,755 | $59K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,660 | $51K |
| 80050 | General health panel | <1% | 1,652 | $50K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 577 | $48K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,470 | $47K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,647 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 883 | $44K |
| 81001 | <1% | 13,549 | $42K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,716 | $38K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,739 | $37K |
| 81025 | <1% | 4,577 | $34K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 50 | $31K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,009 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,792 | $27K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,531 | $25K |
| 87070 | <1% | 3,224 | $25K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 292 | $23K |
| 83880 | <1% | 667 | $22K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 271 | $20K |
| 84484 | <1% | 1,460 | $17K | |
| 83690 | <1% | 2,469 | $14K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 77 | $13K |
| 86803 | <1% | 1,015 | $12K | |
| 62323 | <1% | 31 | $11K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 2,429 | $11K |
| 87150 | <1% | 307 | $9K | |
| 80061 | Lipid panel | <1% | 745 | $8K |
| 87807 | <1% | 614 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 842 | $7K |
| 83605 | <1% | 595 | $6K | |
| 83735 | <1% | 948 | $5K | |
| 82947 | <1% | 1,554 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 50 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 385 | $4K |
| 86885 | <1% | 727 | $4K | |
| 85730 | <1% | 740 | $4K | |
| 85610 | <1% | 746 | $3K | |
| 85379 | <1% | 283 | $2K | |
| 92523 | <1% | 13 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 12 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 24 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 66 | $2K |
| 87081 | <1% | 262 | $2K | |
| 84145 | <1% | 72 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 102 | $2K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 69 | $2K |
| 86592 | <1% | 427 | $1K | |
| 87511 | <1% | 53 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 41 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,143 | $1K |
| 82550 | <1% | 201 | $1K | |
| 84439 | <1% | 145 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,433 | $1K |
| 71250 | <1% | 33 | $963.29 | |
| 82728 | <1% | 94 | $946.08 | |
| 87481 | <1% | 26 | $791.46 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 14 | $730.34 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $678.45 |
| 97597 | <1% | 73 | $622.40 | |
| 82962 | <1% | 234 | $616.12 | |
| 84481 | <1% | 34 | $452.10 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 69 | $430.37 |
| 82803 | <1% | 13 | $301.47 | |
| 84702 | <1% | 26 | $281.19 | |
| 83615 | <1% | 47 | $247.78 | |
| 82570 | <1% | 34 | $147.52 | |
| 84550 | <1% | 34 | $129.39 | |
| 85027 | <1% | 26 | $124.64 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13 | $108.00 |
| 84156 | <1% | 35 | $107.58 | |
| 81050 | <1% | 34 | $106.92 | |
| 86901 | <1% | 33 | $82.46 | |
| 86900 | <1% | 33 | $82.46 | |
| 83550 | <1% | 12 | $46.62 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 405 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 4,970 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 923 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 610 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 199 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 25 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 93 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 28 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 12 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 65 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,802 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 847 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 14 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 13 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVOLINSKI, DOUG (CFO)
| Provider | Location | Paid |
|---|---|---|
| Duncan Regional Hospital, INC | Duncan, OK | $4.15M |
| Duncan Regional Hospital, INC | Duncan, OK | $3.56M |
| Duncan Regional Hospital, INC. | Duncan, OK | $3.41M |
| Duncan Regional Hospital, INC | Marlow, OK | $609K |
| Duncan Regional Hospital, INC. | Waurika, OK | $379K |
| Duncan Regional Hospital, INC | Elgin, OK | $338K |
| Duncan Regional Hospital, INC | Waurika, OK | $18K |
| Duncan Regional Hospital, INC | Duncan, OK | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.